In G1, fewer ercDCs may be sufficient for immunoinhibition in the context of a lower cytotoxic infiltrate and ensuing interaction between T cells, macrophages and tumor cells, which can lead to tumor progression through macrophage-secreted tumor promoting factors, such as CCL8, CCL18 and MMP9, which are part of the ercDC signature. This evidence concerns the gene MMP9 and neoplasm.